Andrew Wardley
Overview
Explore the profile of Andrew Wardley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
4311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Craddock C, Earwaker P, Fittall M, Fontana E, Ganesh D, Gerlinger M, et al.
Camb Prism Precis Med
. 2025 Feb;
3:e1.
PMID: 39944656
Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention...
2.
Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, et al.
Clin Cancer Res
. 2023 Dec;
30(4):895-903.
PMID: 38078899
Purpose: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for...
3.
Velikova G, Morden J, Haviland J, Emery C, Barrett-Lee P, Earl H, et al.
Lancet Oncol
. 2023 Nov;
24(12):1359-1374.
PMID: 37926100
Background: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time...
4.
Maier R, Plummer C, Kasim A, Akhter N, Ogundimu E, Maddox J, et al.
BMJ Open
. 2022 Dec;
12(12):e066252.
PMID: 36585130
Introduction: Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines...
5.
Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, et al.
Eur J Cancer
. 2021 Jul;
153:223-233.
PMID: 34214937
Aims: In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. We evaluated the impact of tucatinib on...
6.
Jackisch C, Cortazar P, Geyer Jr C, Gianni L, Gligorov J, Machackova Z, et al.
Cancer Treat Rev
. 2021 Jun;
99:102229.
PMID: 34139476
Treatment of HER2-positive early breast cancer (EBC) continues to evolve with neoadjuvant (pre-operative) and adjuvant (post-operative) HER2-targeted therapies as standard of care. There are two important decision points. The first...
7.
Wardley A, Cortes J, Provencher L, Miller K, Jo Chien A, Rugo H, et al.
Breast Cancer Res Treat
. 2021 Feb;
187(1):155-165.
PMID: 33591468
Purpose: Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an...
8.
Leone J, Cole B, Regan M, Thurlimann B, Coates A, Rabaglio M, et al.
Cancer
. 2020 Dec;
127(5):700-708.
PMID: 33290610
Background: Endocrine therapy resistance is a major cause of distant recurrence (DR) in hormone receptor-positive breast cancer. This study evaluated differences in survival after DR in patients treated with different...
9.
Thanopoulou E, Khader L, Caira M, Wardley A, Ettl J, Miglietta F, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33182657
Enormous advances have been made in the understanding and treatment of human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) in the last 30 years that have resulted in...
10.
Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey V, et al.
Breast Cancer Res Treat
. 2020 Nov;
185(3):697-707.
PMID: 33159633
Background: Compared to tamoxifen, adjuvant treatment with aromatase inhibitors improves disease outcomes of postmenopausal women with hormone receptor-positive early breast cancer. In the international, randomized, double-blind BIG 1-98 trial, 8010...